IBD 50 stock Exelixis (EXEL) toppled early Thursday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug, cabozantinib, lagged expectations. The biotech company sells cabozantinib under the brand names Cabometyx and Cometriq. The former — a treatment for kidney, liver and thyroid cancers as well as neuroendocrine tumors — brought in $570.6 million in quarterly sales. Cometriq,…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8